Loading patent…
AssigneeMillennium Pharmaceuticals, Inc.
InventorsJohn Joseph Hunter, Mark J. Williamson, Kyle J. MacBeth, Laura A. Rudolph-Owen, Fong-Ying Tsai
Estimating the term…
The present invention relates to methods for the diagnosis and treatment of a cancer or cancer. Specifically, the present invention identifies the differential expression of 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710 genes in tissues relating to cancer, relative to their expression in normal, or non-cancer disease states, and/or in response to manipulations relevant to a cancer. The present invention describes methods for the diagnostic evaluation and prognosis of various cancers, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating a cancer or cancer. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cancer.
A method for identifying a compound capable of treating a tumorigenic disorder or angiogenic disorder, comprising assaying the ability of the compound to modulate 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710 nucleic acid expression or 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710 polypeptide activity, thereby identifying a compound capable of treating a tumoligenic disorder or an angiogenic disorder.
A method for identifying a compound capable of modulating tumorigenesis or angiogenesis comprising:
A method for modulating tumorigenesis or angiogenesis in a cell comprising contacting a cell with a 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710 modulator, thereby modulating tumorigenesis or angiogenesis in the cell.
A method for treating a subject having a tumorigenic disorder or angiogenic disorder characterized by aberrant 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710 polypeptide activity or aberrant 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710 nucleic acid expression comprising administering to the subject a 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710 modulator, thereby treating said subject having a tumorigenic disorder or angiogenic disorder.
Dependencies are inferred from the claim text.